ClinicalTrials.gg

Program

acoramidis

Also written as “Acoramidis”, “Acoramidis (AG10)” and “AG10”.

Its studies are mostly in Amyloid Neuropathies, Familial · Amyloidosis, Hereditary, Transthyretin-Related · Amyloidosis, led by 3 companies.

Furthest: phase 4, since Jul 6, 202615 company-led studies, 6 open or runningNext primary completion: Sep 17, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BridgeBio114 open or runningphase 4since Jul 6, 2026Sep 18, 2017Apr 15, 2028phase 3 · NCT04988386
AstraZeneca31 open or runningphase 4since Dec 15, 2025Nov 6, 2020Mar 31, 2028phase 4 · NCT07306949
Bayer11 open or runningphase 4since Dec 11, 2025Dec 11, 2025Sep 17, 2027phase 4 · NCT07298044

Also a collaborator on its studies: celerion.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Sep 18, 2017.

  1. May 11, 2018Phase 2 study in Amyloid Neuropathies, FamilialBridgeBio · NCT03536767 · 47 enrolled · United States
  2. Feb 27, 2019Phase 3 study in AmyloidosisBridgeBio · NCT03860935 · 632 enrolled · United States, Australia, Belgium and more
  3. May 22, 2020Phase 3 study in Amyloid Neuropathies, FamilialBridgeBio · NCT04418024 · United States
  4. Nov 6, 2020AstraZeneca's first study: phase 3 study in Symptomatic Transthyretin Amyloid CardiomyopathyNew to AstraZenecaAstraZeneca · NCT04622046 · 25 enrolled · Japan
  5. Feb 19, 2021Phase 1 study in AmyloidosisBridgeBio · NCT04769479 · 14 enrolled · United Kingdom
  6. Apr 29, 2021Phase 3 study in Amyloid Neuropathies, FamilialBridgeBio · NCT04882735
  7. Jul 1, 2021Phase 1 study in HealthyAstraZeneca · NCT04958135 · 18 enrolled · United States
  8. Jul 13, 2021Phase 3 study in Amyloid Neuropathies, FamilialBridgeBio · NCT04988386 · 389 enrolled · United States, Australia, Belgium and more
  9. Aug 5, 2024Phase 3 study in AmyloidosisBridgeBio · NCT06563895 · 587 planned · United States, Argentina, Australia and more
  10. Aug 7, 2025Phase 3 study in Amyloidosis, FamilialBridgeBio · NCT07116473 · 250 planned
  11. Dec 11, 2025Bayer's first study: phase 4 study in Transthyretin Amyloid CardiomyopathyNew to BayerBayer · NCT07298044 · 50 planned · Austria, Belgium, Germany and more
  12. Dec 15, 2025Phase 4 study in Transthyretin-type Cardiac AmyloidosisAstraZeneca · NCT07306949 · 200 planned · Japan
  13. Jul 6, 2026Phase 4 study in AmyloidosisBridgeBio · NCT07695701 · 150 planned · United States
  14. Oct 14, 2026Phase 2 study terminatedStudy stoppedNCT03536767 · “Study ended by the sponsor due to meeting Study Objectives”

Ahead

  1. Sep 17, 2027Primary completion: phase 4 study in Transthyretin Amyloid CardiomyopathyBayer · NCT07298044
  2. Mar 31, 2028Primary completion: phase 4 study in Transthyretin-type Cardiac AmyloidosisAstraZeneca · NCT07306949
  3. Apr 15, 2028Primary completion: phase 3 study in Amyloid Neuropathies, FamilialBridgeBio · NCT04988386
  4. Aug 2030Primary completion: phase 4 study in AmyloidosisBridgeBio · NCT07695701

TargetBeta

TTR →read by rule
“Transthyretin stabiliser; Transthyretin stabiliser”ChEMBL 37, by rule

Other programs on TTR

ProgramCompanyFurthest phaseStudies
tafamidisrulePfizerphase 429
coramitugNovo Nordiskphase 33
coramitugNovo Nordiskphase 12

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07695701Amyloidosis · United States4RecruitingBridgeBioAug 2030150
NCT07306949Transthyretin-type Cardiac Amyloidosis · Japan4RecruitingAstraZenecaMar 31, 2028200
NCT07298044Transthyretin Amyloid Cardiomyopathy · Austria, Belgium, Germany and more4RecruitingBayerSep 17, 202750
NCT07116473Amyloidosis, Familial3Not yet recruitingBridgeBioNov 2037250
NCT06563895Amyloidosis · United States, Argentina, Australia and more3RecruitingBridgeBioOct 2031587
NCT04988386Amyloid Neuropathies, Familial · United States, Australia, Belgium and more3Active, not recruitingBridgeBioApr 15, 2028389
NCT04958135Healthy · United States1CompletedAstraZenecaAug 4, 202118
NCT04882735Amyloid Neuropathies, Familial3WithdrawnBridgeBioSep 20260
NCT04769479Amyloidosis · United Kingdom1CompletedBridgeBioAug 4, 202114
NCT04622046Symptomatic Transthyretin Amyloid Cardiomyopathy · Japan3CompletedAstraZenecaNov 8, 202325
NCT04418024Amyloid Neuropathies, Familial · United States3WithdrawnBridgeBioMar 31, 20240
NCT03860935Amyloidosis · United States, Australia, Belgium and more3CompletedBridgeBioMay 11, 2023632
NCT03536767Amyloid Neuropathies, Familial · United States2TerminatedBridgeBioSep 15, 202547
NCT03458130Familial ATTR-CM (ATTRm-CM, or FAC) · United States2CompletedBridgeBioOct 5, 201849
NCT03294707Amyloid Neuropathies, Familial · United States1CompletedBridgeBioFeb 5, 201856

How it is read

Names in the registry

  • “Acoramidis”, 6 entries
  • “Acoramidis (AG10)”, 2 entries
  • “AG10”, 2 entries
  • “acoramidis”, 2 entries
  • “Acoramidis (AG10) oral tablet”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.